PriceTargets.com logo

NASDAQ:RVNC - Revance Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $25.20
  • Forecasted Upside: 86.39 %
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$13.52 As of 10/27/2021 05:00 PM ET
▼ -0.49 (-3.50%)

This chart shows the closing price for RVNC by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Revance Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for RVNC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for RVNC

Analyst Price Target is $25.20
▲ +86.39% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Revance Therapeutics in the last 3 months. The average price target is $25.20, with a high forecast of $36.00 and a low forecast of $17.00. The average price target represents a 86.39% upside from the last price of $13.52.

This chart shows the closing price for RVNC for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 5 polled investment analysts is to buy stock in Revance Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 7 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
5/5/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
8/3/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
11/1/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
1/30/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/30/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/29/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/27/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/27/2021

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/26/2021BarclaysLower Price TargetOverweight$33.00 ➝ $22.00Low
10/25/2021Wells Fargo & CompanyDowngradeOverweight ➝ Equal Weight$35.00 ➝ $17.00Low
10/18/2021Needham & Company LLCLower Price TargetBuy$45.00 ➝ $25.00High
10/13/2021MizuhoReiterated RatingBuy$36.00Low
10/13/2021HC WainwrightReiterated RatingBuy$35.00 ➝ $26.00High
8/6/2021BarclaysBoost Price TargetOverweight$32.00 ➝ $33.00High
5/11/2021MizuhoLower Price TargetBuy$37.00 ➝ $36.00Low
4/23/2021MizuhoBoost Price TargetBuy$33.00 ➝ $37.00High
4/14/2021Needham & Company LLCReiterated RatingBuy$45.00Medium
2/23/2021MizuhoBoost Price TargetPositive ➝ Buy$30.00 ➝ $33.00High
2/23/2021HC WainwrightBoost Price TargetBuy$33.00 ➝ $35.00High
1/8/2021Needham & Company LLCBoost Price TargetBuy$42.00 ➝ $45.00High
11/10/2020MizuhoLower Price TargetBuy$32.00 ➝ $30.00High
10/26/2020BarclaysBoost Price TargetOverweight$35.00 ➝ $38.00Medium
10/15/2020Needham & Company LLCBoost Price TargetBuy$36.00 ➝ $42.00Low
10/15/2020HC WainwrightBoost Price TargetBuy$27.00 ➝ $33.00Low
9/28/2020BarclaysBoost Price TargetOverweight$32.00 ➝ $35.00Low
8/11/2020MizuhoInitiated CoverageBuy$32.00Low
7/10/2020HC WainwrightReiterated RatingBuy$27.00Medium
6/2/2020HC WainwrightReiterated RatingBuy$24.00Medium
5/20/2020MizuhoReiterated RatingBuy$35.00Low
4/16/2020Stifel NicolausLower Price TargetBuy$35.00 ➝ $31.00High
4/15/2020Needham & Company LLCReiterated RatingBuy$36.00High
4/1/2020MizuhoReiterated RatingBuy$39.00 ➝ $35.00High
3/27/2020William BlairReiterated RatingBuyMedium
3/27/2020HC WainwrightReiterated RatingBuy$28.00 ➝ $24.00Medium
3/22/2020The Goldman Sachs GroupDowngradeBuy ➝ Neutral$32.00 ➝ $15.00Medium
2/26/2020HC WainwrightReiterated RatingBuy$23.00 ➝ $28.00Low
2/25/2020Piper SandlerBoost Price TargetOverweight$37.00 ➝ $40.00High
2/25/2020Needham & Company LLCBoost Price TargetBuy$32.00 ➝ $36.00High
2/18/2020Piper SandlerLower Price TargetOverweight$38.00 ➝ $37.00Low
1/23/2020MizuhoBoost Price TargetBuy ➝ Positive$34.00 ➝ $39.00Low
12/2/2019The Goldman Sachs GroupInitiated CoverageBuy$25.00High
11/5/2019MizuhoReiterated RatingBuy$34.00High
10/30/2019Wells Fargo & CompanyUpgradeMarket Perform ➝ Outperform$12.50 ➝ $20.00High
10/15/2019HC WainwrightSet Price TargetBuy$23.00Medium
10/14/2019MizuhoReiterated RatingBuy$34.00High
8/6/2019William BlairReiterated RatingOutperformHigh
6/11/2019BarclaysInitiated CoverageOverweight ➝ Overweight$28.00Medium
4/24/2019MizuhoReiterated RatingBuy$37.00Medium
3/1/2019SunTrust BanksLower Price TargetPositive ➝ Buy$29.00High
2/27/2019MizuhoReiterated RatingBuyHigh
2/15/2019Wells Fargo & CompanyInitiated CoverageMarket Perform$17.83Low
2/14/2019HC WainwrightInitiated CoverageBuy$25.00Low
1/28/2019Stifel NicolausInitiated CoverageBuy$50.00High
1/18/2019MizuhoReiterated RatingBuyMedium
11/16/2018GuggenheimUpgradeNeutral ➝ Buy$41.00Low
11/1/2018Cantor FitzgeraldReiterated RatingBuy$50.00High
9/17/2018Piper Jaffray CompaniesReiterated RatingBuyLow
9/17/2018JMP SecuritiesDowngradeOutperform ➝ Market PerformHigh
9/14/2018Cantor FitzgeraldReiterated RatingBuy$50.00Low
8/2/2018Cantor FitzgeraldSet Price TargetBuy$50.00High
5/29/2018Cantor FitzgeraldSet Price TargetBuy$50.00High
5/8/2018Cantor FitzgeraldSet Price TargetBuy$50.00High
4/20/2018GuggenheimReiterated RatingHoldHigh
4/20/2018MizuhoLower Price TargetBuy$54.00 ➝ $48.00High
4/2/2018Cantor FitzgeraldReiterated RatingBuy$50.00Medium
3/26/2018Needham & Company LLCInitiated CoverageBuy$42.00Low
3/5/2018The Goldman Sachs GroupInitiated CoverageBuy ➝ Buy$60.00Medium
3/1/2018Piper Jaffray CompaniesSet Price TargetBuy$48.00High
3/1/2018William BlairReiterated RatingOutperformMedium
2/28/2018Cantor FitzgeraldSet Price TargetBuy$50.00Medium
1/17/2018CowenSet Price TargetBuy$55.00Low
1/9/2018GuggenheimDowngradeBuy ➝ HoldN/A
1/5/2018MizuhoReiterated RatingBuy$54.00Low
1/4/2018GuggenheimReiterated RatingBuy ➝ Neutral$42.00High
1/4/2018Cantor FitzgeraldSet Price TargetBuy$50.00Low
12/19/2017BarclaysSet Price TargetOverweight ➝ Buy$40.00High
12/13/2017Cantor FitzgeraldSet Price TargetBuy$50.00Low
12/8/2017SunTrust BanksBoost Price TargetBuy$53.00Medium
12/6/2017MizuhoBoost Price TargetBuy ➝ Buy$37.00 ➝ $54.00Medium
12/5/2017GuggenheimInitiated CoverageBuy ➝ Buy$42.00Medium
12/5/2017Piper Jaffray CompaniesBoost Price TargetPositive ➝ Overweight$28.00 ➝ $51.00High
12/5/2017Cantor FitzgeraldSet Price TargetBuy$50.00High
11/29/2017Cantor FitzgeraldSet Price TargetBuy$50.00High
11/27/2017BarclaysInitiated CoverageOverweight$31.00Medium
11/16/2017Cantor FitzgeraldSet Price TargetBuy$50.00N/A
11/16/2017MizuhoInitiated CoverageBuy ➝ Buy$37.00N/A
10/27/2017Piper Jaffray CompaniesReiterated RatingBuy$28.00N/A
10/24/2017Cantor FitzgeraldSet Price TargetBuy$50.00N/A
9/26/2017Cantor FitzgeraldReiterated RatingBuy$50.00High
9/6/2017Cantor FitzgeraldReiterated RatingBuy$50.00Low
8/22/2017JMP SecuritiesInitiated CoverageMkt Outperform ➝ Outperform$34.00Medium
7/26/2017Piper Jaffray CompaniesSet Price TargetBuy$28.00Low
7/20/2017Cantor FitzgeraldInitiated CoverageOverweight$50.00High
6/8/2017AegisReiterated RatingBuy$36.00Medium
5/19/2017AegisReiterated RatingBuy$28.00 ➝ $36.00Low
5/1/2017AegisReiterated RatingBuy$28.00High
2/28/2017AegisReiterated RatingBuy$28.00N/A
1/19/2017AegisReiterated RatingBuy$28.00N/A
1/8/2017AegisSet Price TargetBuy$28.00N/A
11/29/2016AegisInitiated CoverageBuy$28.00N/A
(Data available from 10/27/2016 forward)

News Sentiment Rating

-0.11 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/31/2021
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/30/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/30/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/29/2021
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/29/2021
  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/28/2021
  • 1 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/27/2021
  • 6 very positive mentions
  • 30 positive mentions
  • 16 negative mentions
  • 8 very negative mentions
Mentions as of
10/27/2021

Current Sentiment

  • 6 very positive mentions
  • 30 positive mentions
  • 16 negative mentions
  • 8 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Revance Therapeutics logo
Revance Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development, manufacturing, and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic applications. The firm focuses on production of daxibotulinumtoxinA, a botulinum toxin, for aesthetic and therapeutic indications including facial wrinkles and muscle movement disorders. The company was founded by Jacob M. Waugh and L. Daniel Browne on August 10, 1999 and is headquartered in Nashville, TN.
Read More

Today's Range

Now: $13.52
Low: $13.33
High: $13.98

50 Day Range

MA: $26.49
Low: $13.81
High: $29.72

52 Week Range

Now: $13.52
Low: $13.01
High: $33.83

Volume

913,825 shs

Average Volume

607,806 shs

Market Capitalization

$971.14 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.24

Frequently Asked Questions

What sell-side analysts currently cover shares of Revance Therapeutics?

The following Wall Street sell-side analysts have issued reports on Revance Therapeutics in the last year: Barclays PLC, HC Wainwright, Mizuho, Needham & Company LLC, Wells Fargo & Company, and Zacks Investment Research.
View the latest analyst ratings for RVNC.

What is the current price target for Revance Therapeutics?

5 Wall Street analysts have set twelve-month price targets for Revance Therapeutics in the last year. Their average twelve-month price target is $25.20, suggesting a possible upside of 79.9%. Mizuho has the highest price target set, predicting RVNC will reach $36.00 in the next twelve months. Wells Fargo & Company has the lowest price target set, forecasting a price of $17.00 for Revance Therapeutics in the next year.
View the latest price targets for RVNC.

What is the current consensus analyst rating for Revance Therapeutics?

Revance Therapeutics currently has 1 hold rating and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe RVNC will outperform the market and that investors should add to their positions of Revance Therapeutics.
View the latest ratings for RVNC.

How do I contact Revance Therapeutics' investor relations team?

Revance Therapeutics' physical mailing address is 7555 GATEWAY BLVD., NEWARK CA, 94560. The biopharmaceutical company's listed phone number is (615) 724-7755 and its investor relations email address is [email protected] The official website for Revance Therapeutics is www.revance.com.